2Q 2023 Financial Results August 8, 2023 1 2 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Puneet Souda - SVB Securities David Westenberg - Piper Sandler Dan Brennan - TD Cowen Andrew Brackmann - William Blair David Delahunt - Goldman Sachs ...

FirstQuarter 2023 Earnings Results May 8, 2023 1 2 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdictio ...

NeoGenomics, Inc. (NASDAQ:NEO) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Alex Nowak - Craig-Hallum Mark Massaro - BTIG Andrew Brackmann - William Blair Puneet Souda - SVB Securities Tejas Savant - Morga ...

Saving lives by improving patient care. 4th Quarter 2022 Earnings Results February 23rd, 2023 1 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to re ...

Saving lives by improving patient care. 3 rd Quarter 2022 Earnings Results November 8th, 2022 1 2 Forward looking statement This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to r ...

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial Officer Vishal Sikri - President of our Pharma Services Division, Inivata Shashi Kulkarni - President of Lab Operations and CSO Conference Call Participants Alex Nowak - Craig-Hallam Capital Andrew Brackmann - William Blair David Delahunt - Goldman Sachs Puneet Souda - SVB Securities Andrew Cooper - Raymond James Mark Massaro - B ...

| --- | --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | | August 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer t ...